NASDAQ : NXL
Nexalin Technology, Inc. — Key statistics
Healthcare · Medical Devices · United States
Last price 1.6 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.33M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.33M |
| Enterprise Value | 322,079 |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 829,398 |
| Shares Outstanding | 829,398 |
| Shares Change (YoY) | +52.00% |
| Shares Change (QoQ) | +6.67% |
| Owned by Insiders (%) | 9.29% |
| Owned by Institutions (%) | 3.41% |
| Float | 706,176 |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.11 |
| Forward PS | n/a |
| PB Ratio | 0.77 |
| P/TBV Ratio | 3.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.25 |
| Quick Ratio | 0.71 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -240.25% |
| Return on Assets (ROA) | -119.22% |
| Return on Invested Capital (ROIC) | -152.45% |
| Return on Capital Employed (ROCE) | -600.62% |
| Weighted Average Cost of Capital (WACC) | 26.86% |
| Revenue Per Employee | $27,144 |
| Profits Per Employee | -$1.12M |
| Employee Count | 8 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0.13 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 4.11 |
| 52-Week Price Change | -96.56% |
| 50-Day Moving Average | 4.61 |
| 200-Day Moving Average | 10.90 |
| Relative Strength Index (RSI) | 26.17 |
| Average Volume (20 Days) | 97,505 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 4,482 |
| Short Previous Month | 13,067 |
| Short % of Shares Out | 0.54% |
| Short % of Float | 0.63% |
| Short Ratio (days to cover) | n/a |
Incomestatement
| Measure | Value |
|---|
| Revenue | 217,155 |
| Gross Profit | 187,097 |
| Operating Income | -9.13M |
| Pretax Income | -8.99M |
| Net Income | -8.99M |
| EBITDA | -9.08M |
| EBIT | -9.13M |
| Loss Per Share | -$13.92 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.00M |
| Total Debt | n/a |
| Net Cash | 1.00M |
| Net Cash Per Share | $1.21 |
| Equity (Book Value) | 1.52M |
| Book Value Per Share | 2.07 |
| Working Capital | 377,350 |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -6.13M |
| Capital Expenditures | -49,276 |
| Depreciation & Amortization | 45,530 |
| Net Borrowing | n/a |
| Free Cash Flow | -6.18M |
| FCF Per Share | -$7.45 |
Margins
| Measure | Value |
|---|
| Gross Margin | 86.16% |
| Operating Margin | -4,202.54% |
| Pretax Margin | -4,139.38% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -52.00% |
| Shareholder Yield | -52.00% |
| Earnings Yield | -870.02% |
| FCF Yield | -465.56% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 31, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -49.51 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |